SecBot SecBot
ANALYST-DOWNGRADE ·Filed Sep 3, 2026

MRNA

Moderna, Inc.
BEARISH
Impact 6/10
Horizonmonths Processed2mo ago SECanalyst-MRNA-rothschi-20260903
Rothschild & Co double downgrade: Neutral → Sell
Actionable Insight ▼ Bearish

The double downgrade aligns with heavy insider selling and institutional trimming, a rare convergence of bearish signals. Traders should monitor the $112.56 mean target as a near-term floor; any bounce above $170 is unlikely given the consensus high target and bearish momentum.

DirectionBearish
Confidencemedium
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$148.87
T+0 close · Sep 3, 2026 · via day close
Latest settled
+27.63%
T+20 · $190.01 · next T+60 in 13d
Vs SPY
+28.82%
α at T+20
Latest observation
+116.26%
T+51 · FF3 residual α
  1. T+0 · Sep 3 $148.87entry
  2. T+1 · 2mo ago −2.23%α −1.84% · $145.55
  3. T+5 · 2mo ago −3.29%α −2.14% · $143.97
  4. T+20 · 7w ago +27.63%α +28.82% · $190.01
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rothschild & Co double downgraded Moderna from Neutral to Sell on Sep 3, 2026, slashing the price target from $40 to $81 (a 102.5% increase but representing a 46.3% downside from the current price of $150.81). The firm carries a 57% accuracy rate on 40 calls and an average return of 3.1%, placing it below the top-tier firms covering MRNA. The consensus stands at a mix of 11 Buy, 17 Hold, 2 Sell, with a mean target of $112.56 implying a 25.4% downside. Analyst activity over the past 30 days shows 3 upgrades vs 1 downgrade, but EPS revisions for FY0 are net positive (13 up, 5 down), suggesting some improving fundamental expectations. Insiders have been selling heavily, notably CEO Stephane Bancel sold $28.74M in August 2026, while institutional moves include Citadel trimming by 39.9% and JPMorgan trimming 36.4%, though Norges Bank opened a $211.9M new position. Short interest stands at 62.7% of float, indicating heavy bearish positioning. The Rothschild call is contrarian, a rare double downgrade from a below-top-tier firm, but the massive insider sales and institutional trimming lend support to the bearish stance.

Impact Score

Base Score
5/7
LLM Adjustment
+1
Final Score
6/10

Consensus & Targets

Buy / Strong Buy
11 (37%)
Hold
17
Sell / Strong Sell
2
Total Analysts
18
Mean PT
$112.56
Median PT
$125.00
High PT
$170.00
Low PT
$40.00
Current Price
$150.81
Implied Upside
-25.4%

The consensus is mixed: 11 Buy (4 Strong Buy, 7 Buy), 17 Hold, 2 Sell, out of 30 analysts. The overall directional stance is Hold-tilted with 36.7% Buy, 56.7% Hold, 6.7% Sell. Rothschild's Sell rating places it more bearish than consensus.

The mean price target is $112.56 (-25.4% vs $150.81), median $125.00 (-17.1%), high $170.00 (+12.7%), low $40.00 (-73.5%). Rothschild's $81 target is below the median and mean, aligning more with the bearish side of the range, above the low but well below consensus.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-09-03Rothschild & CodowngradeSell$81.00
2026-08-28Argus ResearchupgradeBuyNo target
2026-08-25Wolfe ResearchupgradePeer PerformNo target
2026-08-24BarclaysmaintainEqual-Weight$125.00
2026-08-21JP MorganmaintainUnderweight$77.00
2026-08-20Goldman SachsmaintainNeutral$120.00
2026-08-20UBSmaintainNeutral$150.00
2026-08-20Morgan StanleymaintainEqual-Weight$89.00
2026-08-19William BlairupgradeOutperformNo target
2026-08-03CitigroupmaintainNeutral$60.00

Over the past 30 days, MRNA has seen 3 upgrades (Argus Research, Wolfe Research, William Blair) and 1 downgrade (Rothschild). EPS revisions for the current fiscal year (FY0) are net positive: 13 upward revisions vs 5 downward in the last 30 days, and the consensus EPS estimate improved from -$8.70 to -$8.54. For the next quarter (+1q), 11 up vs 3 down in 30 days.

Firm Track Record: Rothschild & Co

Rothschild & Co accuracy: 57% on 40 calls | avg return: 3.1%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 13 firms with ≥5 scored calls.

FirmAccuracyCallsAvg Returnvs Average
Jefferies100%2/242.6%top tier
Morgan Stanley75%3/426.9%top tier
B of A Securities67%2/310%top tier
Leerink Partners50%1/248.9%below average
Citigroup50%1/231.7%below average
JP Morgan50%3/6-7.9%below average
RBC Capital38%3/8-7.9%below average
Needham38%3/8-14.3%below average
Barclays33%2/6-7.5%below average
Piper Sandler25%1/44.5%below average

Rothschild & Co has a 57% accuracy rate on 40 calls and an average return of 3.1%, ranking it as below-average relative to the top firms (Jefferies 100% on 2 calls, Morgan Stanley 75% on 4, BofA 67% on 3). The best performing is Jefferies (100% accuracy, 42.6% avg return); the worst is Oppenheimer (0% on 2, -41.8% avg return).

Earnings Estimates

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
0q$-1.35$-3.32 to $-0.80$876.6M↑7 ↓0
+1q$-1.86$-2.31 to $-1.20$685.0M↑11 ↓0
0y$-8.54$-10.55 to $-8.00$2.1B↑7 ↓0
+1y$-4.91$-7.11 to $-2.73$2.4B↑8 ↓0

Cross-Platform Signals

Insider Trades (90d)
0 buys / 5 sells
Institutional
CITADEL ADVISORS LLC: trim (-39.9%)
Institutional
JPMORGAN CHASE & CO: trim (-36.4%)
Institutional
NORGES BANK: new
Short Interest
Short: 5,363,276 | Exempt: 16,878 | TRF Vol: 8,549,149 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)

Insider trades are bearish: CEO Stephane Bancel sold $28.74M on Aug 5, 2026, and EVP Stephen Hoge sold $3.61M on Jul 15. No insider buys are present. Institutional activity shows divergence: Citadel trimmed 39.9% and JPMorgan trimmed 36.4%, while Norges Bank opened a $211.9M new position and Bank of Montreal added 30.9%. The insider selling aligns with the bearish downgrade, slightly strengthening its signal. No congressional trades were recorded. Short interest at 62.7% of float is extremely high, indicating heavy bearish bets.

Investment Themes

Documents Analyzed

Report based on filing metadata.

Track record

26 reports on MRNA

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Viewing Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026